Literature DB >> 1744713

Fluorine-18-altanserin: a radioligand for the study of serotonin receptors with PET: radiolabeling and in vivo biologic behavior in rats.

C Lemaire1, R Cantineau, M Guillaume, A Plenevaux, L Christiaens.   

Abstract

No-carrier-added [18F]altanserin was synthesized by nucleophilic substitution of the corresponding nitro compound with [18F]fluoride in the presence of kryptofix 222 and K2CO3. After purification by preparative HPLC, [18F]altanserin was produced in less than 2 hr with a radiochemical yield of 10% (EOS) and a specific activity of 0.8-1.3 Ci/mumol. In rats, the tracer localized rapidly in the whole brain (0.5% ID/g organ) with a high binding to the frontal cortex. The frontal cortex/cerebellum ratio increased with time and reached a plateau of 11 at 2 hr postinjection. This uptake in S2 receptor regions was saturable and could be blocked by pretreatment with various S2 antagonists. This radiopharmaceutical appears to be more selective for S2 receptor sites than other ligands available today and allows the study of S2 receptors under in vivo conditions.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1744713

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  26 in total

1.  Evaluation of [(11)C]metergoline as a PET radiotracer for 5HTR in nonhuman primates.

Authors:  Jacob M Hooker; Sung Won Kim; Achim T Reibel; David Alexoff; Youwen Xu; Colleen Shea
Journal:  Bioorg Med Chem       Date:  2010-04-20       Impact factor: 3.641

Review 2.  Tracers for metabolic imaging of brain and heart. Radiochemistry and radiopharmacology.

Authors:  G Stöcklin
Journal:  Eur J Nucl Med       Date:  1992

3.  Medial prefrontal cortex 5-HT(2A) density is correlated with amygdala reactivity, response habituation, and functional coupling.

Authors:  Patrick M Fisher; Carolyn C Meltzer; Julie C Price; Rhaven L Coleman; Scott K Ziolko; Carl Becker; Eydie L Moses-Kolko; Sarah L Berga; Ahmad R Hariri
Journal:  Cereb Cortex       Date:  2009-03-25       Impact factor: 5.357

4.  Gender, personality, and serotonin-2A receptor binding in healthy subjects.

Authors:  Paul H Soloff; Julie C Price; Neale Scott Mason; Carl Becker; Carolyn C Meltzer
Journal:  Psychiatry Res       Date:  2010-01-30       Impact factor: 3.222

Review 5.  Radioligands for brain 5-HT2 receptor imaging in vivo: why do we need them?

Authors:  G F Busatto
Journal:  Eur J Nucl Med       Date:  1996-08

6.  Effects of serotonin-2A receptor binding and gender on personality traits and suicidal behavior in borderline personality disorder.

Authors:  Paul H Soloff; Laurel Chiappetta; Neale Scott Mason; Carl Becker; Julie C Price
Journal:  Psychiatry Res       Date:  2014-03-29       Impact factor: 3.222

Review 7.  From simultaneous to synergistic MR-PET brain imaging: A review of hybrid MR-PET imaging methodologies.

Authors:  Zhaolin Chen; Sharna D Jamadar; Shenpeng Li; Francesco Sforazzini; Jakub Baran; Nicholas Ferris; Nadim Jon Shah; Gary F Egan
Journal:  Hum Brain Mapp       Date:  2018-08-04       Impact factor: 5.038

8.  Trait Openness and serotonin 2A receptors in healthy volunteers: A positron emission tomography study.

Authors:  Dea Siggaard Stenbaek; Sara Kristiansen; Daniel Burmester; Martin Korsbak Madsen; Vibe Gedsoe Frokjaer; Gitte Moos Knudsen; Patrick MacDonald Fisher
Journal:  Hum Brain Mapp       Date:  2019-01-11       Impact factor: 5.038

9.  Multicompartmental study of fluorine-18 altanserin binding to brain 5HT2 receptors in humans using positron emission tomography.

Authors:  F Biver; S Goldman; A Luxen; M Monclus; M Forestini; J Mendlewicz; F Lotstra
Journal:  Eur J Nucl Med       Date:  1994-09

10.  Altered 5-HT(2A) receptor binding after recovery from bulimia-type anorexia nervosa: relationships to harm avoidance and drive for thinness.

Authors:  Ursula F Bailer; Julie C Price; Carolyn C Meltzer; Chester A Mathis; Guido K Frank; Lisa Weissfeld; Claire W McConaha; Shannan E Henry; Sarah Brooks-Achenbach; Nicole C Barbarich; Walter H Kaye
Journal:  Neuropsychopharmacology       Date:  2004-06       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.